Nov 08, 2023 / 03:30PM GMT
Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst
I'm Ellie Merle, one of the biotech analyst here at UBS. Thank you for joining us in a very sunny Miami for the UBS Biopharma Conference. Very happy to have Kymera Therapeutics here with us today for a fireside chat. Joining us from Kymera is Nello Mainolfi, President and Chief Executive Officer.
With that, Nello, thank you so much for joining us.
Questions and Answers:
Nello Mainolfi - Kymera Therapeutics, Inc. - Co-Founder, President, CEO & DirectorThanks, Ellie, for having us.
Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst
Of course. And listen, there's a lot of talk around targeted protein degradation. What this could mean as a modality? I think investor feedback recently has been come back in terms of excitement, so relative to 2 years ago. In your view, what do you think people are missing? What have we learned about this modality in the last couple of years from all the clinical data? And what do
Trustpilot
